nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—ALB—atherosclerosis	0.133	1	CbGaD
Gefitinib—ABCG2—Rosuvastatin—atherosclerosis	0.0466	0.083	CbGbCtD
Gefitinib—ABCG2—Ezetimibe—atherosclerosis	0.0466	0.083	CbGbCtD
Gefitinib—ABCG2—Pravastatin—atherosclerosis	0.0424	0.0755	CbGbCtD
Gefitinib—ALB—Rosuvastatin—atherosclerosis	0.0321	0.0572	CbGbCtD
Gefitinib—CYP3A5—Rosuvastatin—atherosclerosis	0.0258	0.046	CbGbCtD
Gefitinib—CYP3A5—Simvastatin—atherosclerosis	0.024	0.0428	CbGbCtD
Gefitinib—CYP3A5—Pravastatin—atherosclerosis	0.0235	0.0418	CbGbCtD
Gefitinib—CYP3A5—Lovastatin—atherosclerosis	0.0235	0.0418	CbGbCtD
Gefitinib—CYP2C19—Rosuvastatin—atherosclerosis	0.0208	0.0371	CbGbCtD
Gefitinib—CYP2C19—Simvastatin—atherosclerosis	0.0194	0.0345	CbGbCtD
Gefitinib—CYP2C19—Lovastatin—atherosclerosis	0.019	0.0337	CbGbCtD
Gefitinib—CYP2D6—Niacin—atherosclerosis	0.0186	0.0332	CbGbCtD
Gefitinib—CYP2C9—Rosuvastatin—atherosclerosis	0.0173	0.0308	CbGbCtD
Gefitinib—ABCB1—Ezetimibe—atherosclerosis	0.0168	0.0299	CbGbCtD
Gefitinib—CYP2C9—Simvastatin—atherosclerosis	0.0161	0.0287	CbGbCtD
Gefitinib—CYP2C9—Lovastatin—atherosclerosis	0.0158	0.0281	CbGbCtD
Gefitinib—CYP2C9—Pravastatin—atherosclerosis	0.0158	0.0281	CbGbCtD
Gefitinib—ABCB1—Simvastatin—atherosclerosis	0.0156	0.0278	CbGbCtD
Gefitinib—ABCB1—Pravastatin—atherosclerosis	0.0153	0.0272	CbGbCtD
Gefitinib—ABCB1—Lovastatin—atherosclerosis	0.0153	0.0272	CbGbCtD
Gefitinib—CYP2D6—Simvastatin—atherosclerosis	0.0147	0.0262	CbGbCtD
Gefitinib—CYP2D6—Pravastatin—atherosclerosis	0.0144	0.0257	CbGbCtD
Gefitinib—CYP2D6—Lovastatin—atherosclerosis	0.0144	0.0257	CbGbCtD
Gefitinib—STK10—renal artery—atherosclerosis	0.0122	0.326	CbGeAlD
Gefitinib—CYP3A4—Rosuvastatin—atherosclerosis	0.0101	0.0179	CbGbCtD
Gefitinib—CYP3A4—Ezetimibe—atherosclerosis	0.0101	0.0179	CbGbCtD
Gefitinib—CYP3A4—Simvastatin—atherosclerosis	0.00937	0.0167	CbGbCtD
Gefitinib—CYP3A4—Pravastatin—atherosclerosis	0.00917	0.0163	CbGbCtD
Gefitinib—CYP3A4—Lovastatin—atherosclerosis	0.00917	0.0163	CbGbCtD
Gefitinib—CHEK2—Pitavastatin—Rosuvastatin—atherosclerosis	0.00279	1	CbGdCrCtD
Gefitinib—Vesiculobullous rash—Niacin—atherosclerosis	0.00189	0.0165	CcSEcCtD
Gefitinib—Interstitial lung disease—Ezetimibe—atherosclerosis	0.00171	0.0149	CcSEcCtD
Gefitinib—Proteinuria—Rosuvastatin—atherosclerosis	0.00165	0.0144	CcSEcCtD
Gefitinib—Protein urine present—Rosuvastatin—atherosclerosis	0.00163	0.0142	CcSEcCtD
Gefitinib—Interstitial lung disease—Simvastatin—atherosclerosis	0.00163	0.0142	CcSEcCtD
Gefitinib—Drug interaction—Rosuvastatin—atherosclerosis	0.00157	0.0137	CcSEcCtD
Gefitinib—CHEK2—adipose tissue—atherosclerosis	0.00155	0.0412	CbGeAlD
Gefitinib—Interstitial lung disease—Pravastatin—atherosclerosis	0.00147	0.0129	CcSEcCtD
Gefitinib—Haemoptysis—Niacin—atherosclerosis	0.00143	0.0125	CcSEcCtD
Gefitinib—Tenderness—Lovastatin—atherosclerosis	0.00141	0.0123	CcSEcCtD
Gefitinib—Amblyopia—Niacin—atherosclerosis	0.00137	0.012	CcSEcCtD
Gefitinib—Rash pustular—Niacin—atherosclerosis	0.00133	0.0116	CcSEcCtD
Gefitinib—Tenderness—Simvastatin—atherosclerosis	0.00132	0.0115	CcSEcCtD
Gefitinib—Proteinuria—Simvastatin—atherosclerosis	0.00131	0.0115	CcSEcCtD
Gefitinib—Drug interaction—Ezetimibe—atherosclerosis	0.0013	0.0114	CcSEcCtD
Gefitinib—Protein urine present—Simvastatin—atherosclerosis	0.00129	0.0113	CcSEcCtD
Gefitinib—Drug interaction—Simvastatin—atherosclerosis	0.00124	0.0108	CcSEcCtD
Gefitinib—ERBB3—connective tissue—atherosclerosis	0.00123	0.0328	CbGeAlD
Gefitinib—Bosutinib—CSF1R—atherosclerosis	0.0012	0.342	CrCbGaD
Gefitinib—Tenderness—Pravastatin—atherosclerosis	0.00119	0.0104	CcSEcCtD
Gefitinib—Hepatic failure—Rosuvastatin—atherosclerosis	0.00117	0.0103	CcSEcCtD
Gefitinib—MKNK2—connective tissue—atherosclerosis	0.00117	0.0312	CbGeAlD
Gefitinib—Drug interaction—Pravastatin—atherosclerosis	0.00112	0.00981	CcSEcCtD
Gefitinib—Iloperidone—HRH1—atherosclerosis	0.0011	0.315	CrCbGaD
Gefitinib—MKNK2—cardiovascular system—atherosclerosis	0.00102	0.0272	CbGeAlD
Gefitinib—EGFR—adipose tissue—atherosclerosis	0.00102	0.0271	CbGeAlD
Gefitinib—MKNK1—cardiovascular system—atherosclerosis	0.00101	0.0268	CbGeAlD
Gefitinib—Hepatic failure—Lovastatin—atherosclerosis	0.000995	0.00869	CcSEcCtD
Gefitinib—CSNK1E—adipose tissue—atherosclerosis	0.00098	0.0261	CbGeAlD
Gefitinib—Hepatic failure—Ezetimibe—atherosclerosis	0.000976	0.00852	CcSEcCtD
Gefitinib—IRAK4—adipose tissue—atherosclerosis	0.000965	0.0257	CbGeAlD
Gefitinib—ERBB3—adipose tissue—atherosclerosis	0.000946	0.0252	CbGeAlD
Gefitinib—Hepatic failure—Simvastatin—atherosclerosis	0.00093	0.00813	CcSEcCtD
Gefitinib—MKNK2—adipose tissue—atherosclerosis	0.000899	0.0239	CbGeAlD
Gefitinib—IRAK1—adipose tissue—atherosclerosis	0.000899	0.0239	CbGeAlD
Gefitinib—Pancreatitis—Rosuvastatin—atherosclerosis	0.000894	0.00781	CcSEcCtD
Gefitinib—MKNK1—adipose tissue—atherosclerosis	0.000888	0.0236	CbGeAlD
Gefitinib—Atrial fibrillation—Simvastatin—atherosclerosis	0.000882	0.00771	CcSEcCtD
Gefitinib—Hepatic failure—Pravastatin—atherosclerosis	0.000841	0.00735	CcSEcCtD
Gefitinib—STK10—cardiovascular system—atherosclerosis	0.000829	0.0221	CbGeAlD
Gefitinib—Atrial fibrillation—Niacin—atherosclerosis	0.00081	0.00708	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Lovastatin—atherosclerosis	0.000805	0.00703	CcSEcCtD
Gefitinib—Dermatitis bullous—Niacin—atherosclerosis	0.000803	0.00702	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Ezetimibe—atherosclerosis	0.000789	0.0069	CcSEcCtD
Gefitinib—Haematuria—Rosuvastatin—atherosclerosis	0.000775	0.00677	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.000773	0.00675	CcSEcCtD
Gefitinib—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.000769	0.00672	CcSEcCtD
Gefitinib—Pancreatitis—Lovastatin—atherosclerosis	0.000757	0.00662	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Simvastatin—atherosclerosis	0.000753	0.00658	CcSEcCtD
Gefitinib—Pancreatitis—Ezetimibe—atherosclerosis	0.000743	0.00649	CcSEcCtD
Gefitinib—MAP2K5—cardiovascular system—atherosclerosis	0.000741	0.0197	CbGeAlD
Gefitinib—STK10—adipose tissue—atherosclerosis	0.000731	0.0195	CbGeAlD
Gefitinib—Hepatitis—Rosuvastatin—atherosclerosis	0.00073	0.00637	CcSEcCtD
Gefitinib—Vandetanib—VEGFA—atherosclerosis	0.000719	0.205	CrCbGaD
Gefitinib—EGFR—liver—atherosclerosis	0.000715	0.019	CbGeAlD
Gefitinib—Pancreatitis—Simvastatin—atherosclerosis	0.000708	0.00619	CcSEcCtD
Gefitinib—Dry skin—Niacin—atherosclerosis	0.000704	0.00615	CcSEcCtD
Gefitinib—Dry skin—Pravastatin—atherosclerosis	0.000693	0.00605	CcSEcCtD
Gefitinib—CSNK1E—liver—atherosclerosis	0.000687	0.0183	CbGeAlD
Gefitinib—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.000683	0.00597	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Pravastatin—atherosclerosis	0.000681	0.00595	CcSEcCtD
Gefitinib—IRAK4—liver—atherosclerosis	0.000677	0.018	CbGeAlD
Gefitinib—Infestation NOS—Ezetimibe—atherosclerosis	0.000676	0.0059	CcSEcCtD
Gefitinib—Infestation—Ezetimibe—atherosclerosis	0.000676	0.0059	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.000667	0.00582	CcSEcCtD
Gefitinib—ERBB3—liver—atherosclerosis	0.000663	0.0177	CbGeAlD
Gefitinib—MAP2K5—adipose tissue—atherosclerosis	0.000653	0.0174	CbGeAlD
Gefitinib—Arrhythmia—Rosuvastatin—atherosclerosis	0.000652	0.00569	CcSEcCtD
Gefitinib—Pancreatitis—Pravastatin—atherosclerosis	0.00064	0.0056	CcSEcCtD
Gefitinib—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000639	0.00558	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.000639	0.00558	CcSEcCtD
Gefitinib—MKNK2—liver—atherosclerosis	0.000631	0.0168	CbGeAlD
Gefitinib—IRAK1—liver—atherosclerosis	0.000631	0.0168	CbGeAlD
Gefitinib—MKNK1—liver—atherosclerosis	0.000623	0.0166	CbGeAlD
Gefitinib—Hepatitis—Lovastatin—atherosclerosis	0.000618	0.0054	CcSEcCtD
Gefitinib—Hepatitis—Ezetimibe—atherosclerosis	0.000606	0.0053	CcSEcCtD
Gefitinib—Oedema peripheral—Ezetimibe—atherosclerosis	0.000597	0.00522	CcSEcCtD
Gefitinib—Weight decreased—Pravastatin—atherosclerosis	0.000591	0.00516	CcSEcCtD
Gefitinib—Erythema multiforme—Lovastatin—atherosclerosis	0.000585	0.00511	CcSEcCtD
Gefitinib—Angioedema—Rosuvastatin—atherosclerosis	0.00058	0.00507	CcSEcCtD
Gefitinib—Hepatitis—Simvastatin—atherosclerosis	0.000578	0.00505	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.000577	0.00504	CcSEcCtD
Gefitinib—Stomatitis—Niacin—atherosclerosis	0.000577	0.00504	CcSEcCtD
Gefitinib—Erythema multiforme—Ezetimibe—atherosclerosis	0.000573	0.00501	CcSEcCtD
Gefitinib—Cough—Rosuvastatin—atherosclerosis	0.000554	0.00484	CcSEcCtD
Gefitinib—Angiopathy—Ezetimibe—atherosclerosis	0.00055	0.00481	CcSEcCtD
Gefitinib—Erythema multiforme—Simvastatin—atherosclerosis	0.000547	0.00478	CcSEcCtD
Gefitinib—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000547	0.00478	CcSEcCtD
Gefitinib—Alopecia—Lovastatin—atherosclerosis	0.000546	0.00477	CcSEcCtD
Gefitinib—Alopecia—Ezetimibe—atherosclerosis	0.000536	0.00468	CcSEcCtD
Gefitinib—Haemoglobin—Niacin—atherosclerosis	0.000534	0.00466	CcSEcCtD
Gefitinib—Haemorrhage—Niacin—atherosclerosis	0.000531	0.00464	CcSEcCtD
Gefitinib—Hepatitis—Niacin—atherosclerosis	0.000531	0.00464	CcSEcCtD
Gefitinib—Malnutrition—Ezetimibe—atherosclerosis	0.000528	0.00461	CcSEcCtD
Gefitinib—Oedema peripheral—Niacin—atherosclerosis	0.000523	0.00457	CcSEcCtD
Gefitinib—Hepatitis—Pravastatin—atherosclerosis	0.000523	0.00457	CcSEcCtD
Gefitinib—Infection—Rosuvastatin—atherosclerosis	0.000515	0.0045	CcSEcCtD
Gefitinib—STK10—liver—atherosclerosis	0.000513	0.0137	CbGeAlD
Gefitinib—Alopecia—Simvastatin—atherosclerosis	0.000511	0.00446	CcSEcCtD
Gefitinib—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000508	0.00444	CcSEcCtD
Gefitinib—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000508	0.00443	CcSEcCtD
Gefitinib—Eye disorder—Niacin—atherosclerosis	0.000496	0.00434	CcSEcCtD
Gefitinib—Erythema multiforme—Pravastatin—atherosclerosis	0.000494	0.00432	CcSEcCtD
Gefitinib—Angioedema—Lovastatin—atherosclerosis	0.000492	0.0043	CcSEcCtD
Gefitinib—Anaemia—Ezetimibe—atherosclerosis	0.000488	0.00426	CcSEcCtD
Gefitinib—Malaise—Lovastatin—atherosclerosis	0.000485	0.00424	CcSEcCtD
Gefitinib—Cardiac disorder—Pravastatin—atherosclerosis	0.000485	0.00424	CcSEcCtD
Gefitinib—Angioedema—Ezetimibe—atherosclerosis	0.000482	0.00421	CcSEcCtD
Gefitinib—Angiopathy—Niacin—atherosclerosis	0.000482	0.00421	CcSEcCtD
Gefitinib—Malaise—Ezetimibe—atherosclerosis	0.000476	0.00416	CcSEcCtD
Gefitinib—Arrhythmia—Niacin—atherosclerosis	0.000474	0.00414	CcSEcCtD
Gefitinib—Alopecia—Niacin—atherosclerosis	0.000469	0.0041	CcSEcCtD
Gefitinib—Arrhythmia—Pravastatin—atherosclerosis	0.000467	0.00408	CcSEcCtD
Gefitinib—Anaemia—Simvastatin—atherosclerosis	0.000465	0.00407	CcSEcCtD
Gefitinib—Malnutrition—Niacin—atherosclerosis	0.000462	0.00404	CcSEcCtD
Gefitinib—Alopecia—Pravastatin—atherosclerosis	0.000462	0.00404	CcSEcCtD
Gefitinib—Cough—Ezetimibe—atherosclerosis	0.000461	0.00402	CcSEcCtD
Gefitinib—Angioedema—Simvastatin—atherosclerosis	0.00046	0.00402	CcSEcCtD
Gefitinib—MAP2K5—liver—atherosclerosis	0.000458	0.0122	CbGeAlD
Gefitinib—Malaise—Simvastatin—atherosclerosis	0.000454	0.00397	CcSEcCtD
Gefitinib—Dry mouth—Lovastatin—atherosclerosis	0.000448	0.00392	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000446	0.0039	CcSEcCtD
Gefitinib—Constipation—Rosuvastatin—atherosclerosis	0.000443	0.00387	CcSEcCtD
Gefitinib—Pain—Rosuvastatin—atherosclerosis	0.000443	0.00387	CcSEcCtD
Gefitinib—Dry mouth—Ezetimibe—atherosclerosis	0.00044	0.00384	CcSEcCtD
Gefitinib—Infection—Lovastatin—atherosclerosis	0.000436	0.00381	CcSEcCtD
Gefitinib—Thrombocytopenia—Lovastatin—atherosclerosis	0.00043	0.00376	CcSEcCtD
Gefitinib—Infection—Ezetimibe—atherosclerosis	0.000428	0.00374	CcSEcCtD
Gefitinib—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000424	0.0037	CcSEcCtD
Gefitinib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000423	0.00369	CcSEcCtD
Gefitinib—Angioedema—Niacin—atherosclerosis	0.000422	0.00369	CcSEcCtD
Gefitinib—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000422	0.00369	CcSEcCtD
Gefitinib—Anaemia—Pravastatin—atherosclerosis	0.000421	0.00368	CcSEcCtD
Gefitinib—Anorexia—Lovastatin—atherosclerosis	0.000419	0.00366	CcSEcCtD
Gefitinib—Skin disorder—Ezetimibe—atherosclerosis	0.000419	0.00366	CcSEcCtD
Gefitinib—Angioedema—Pravastatin—atherosclerosis	0.000416	0.00363	CcSEcCtD
Gefitinib—Urticaria—Rosuvastatin—atherosclerosis	0.000412	0.0036	CcSEcCtD
Gefitinib—Malaise—Pravastatin—atherosclerosis	0.00041	0.00359	CcSEcCtD
Gefitinib—Abdominal pain—Rosuvastatin—atherosclerosis	0.00041	0.00358	CcSEcCtD
Gefitinib—Infection—Simvastatin—atherosclerosis	0.000408	0.00357	CcSEcCtD
Gefitinib—Cough—Niacin—atherosclerosis	0.000403	0.00352	CcSEcCtD
Gefitinib—Thrombocytopenia—Simvastatin—atherosclerosis	0.000402	0.00351	CcSEcCtD
Gefitinib—ABCB1—blood vessel—atherosclerosis	0.000398	0.0106	CbGeAlD
Gefitinib—Cough—Pravastatin—atherosclerosis	0.000397	0.00347	CcSEcCtD
Gefitinib—Anorexia—Simvastatin—atherosclerosis	0.000392	0.00342	CcSEcCtD
Gefitinib—Dyspnoea—Lovastatin—atherosclerosis	0.000392	0.00342	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000391	0.00341	CcSEcCtD
Gefitinib—Dry mouth—Niacin—atherosclerosis	0.000385	0.00336	CcSEcCtD
Gefitinib—Dyspnoea—Ezetimibe—atherosclerosis	0.000384	0.00336	CcSEcCtD
Gefitinib—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000382	0.00334	CcSEcCtD
Gefitinib—Decreased appetite—Lovastatin—atherosclerosis	0.000382	0.00334	CcSEcCtD
Gefitinib—Fatigue—Lovastatin—atherosclerosis	0.000379	0.00331	CcSEcCtD
Gefitinib—Constipation—Lovastatin—atherosclerosis	0.000376	0.00328	CcSEcCtD
Gefitinib—Pain—Lovastatin—atherosclerosis	0.000376	0.00328	CcSEcCtD
Gefitinib—Decreased appetite—Ezetimibe—atherosclerosis	0.000375	0.00327	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000372	0.00325	CcSEcCtD
Gefitinib—Asthenia—Rosuvastatin—atherosclerosis	0.000372	0.00325	CcSEcCtD
Gefitinib—ORM1—liver—atherosclerosis	0.000372	0.0099	CbGeAlD
Gefitinib—Fatigue—Ezetimibe—atherosclerosis	0.000371	0.00325	CcSEcCtD
Gefitinib—Shock—Niacin—atherosclerosis	0.000371	0.00324	CcSEcCtD
Gefitinib—Infection—Pravastatin—atherosclerosis	0.000369	0.00322	CcSEcCtD
Gefitinib—Constipation—Ezetimibe—atherosclerosis	0.000368	0.00322	CcSEcCtD
Gefitinib—Pain—Ezetimibe—atherosclerosis	0.000368	0.00322	CcSEcCtD
Gefitinib—Pruritus—Rosuvastatin—atherosclerosis	0.000367	0.0032	CcSEcCtD
Gefitinib—Skin disorder—Niacin—atherosclerosis	0.000366	0.0032	CcSEcCtD
Gefitinib—Dyspnoea—Simvastatin—atherosclerosis	0.000366	0.0032	CcSEcCtD
Gefitinib—Thrombocytopenia—Pravastatin—atherosclerosis	0.000364	0.00318	CcSEcCtD
Gefitinib—Anorexia—Niacin—atherosclerosis	0.00036	0.00314	CcSEcCtD
Gefitinib—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000359	0.00314	CcSEcCtD
Gefitinib—Decreased appetite—Simvastatin—atherosclerosis	0.000357	0.00312	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000355	0.0031	CcSEcCtD
Gefitinib—Diarrhoea—Rosuvastatin—atherosclerosis	0.000355	0.0031	CcSEcCtD
Gefitinib—Fatigue—Simvastatin—atherosclerosis	0.000354	0.00309	CcSEcCtD
Gefitinib—Anorexia—Pravastatin—atherosclerosis	0.000354	0.00309	CcSEcCtD
Gefitinib—Hypotension—Niacin—atherosclerosis	0.000353	0.00308	CcSEcCtD
Gefitinib—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000352	0.00308	CcSEcCtD
Gefitinib—Constipation—Simvastatin—atherosclerosis	0.000351	0.00307	CcSEcCtD
Gefitinib—Pain—Simvastatin—atherosclerosis	0.000351	0.00307	CcSEcCtD
Gefitinib—Urticaria—Lovastatin—atherosclerosis	0.000349	0.00305	CcSEcCtD
Gefitinib—Body temperature increased—Lovastatin—atherosclerosis	0.000347	0.00303	CcSEcCtD
Gefitinib—Abdominal pain—Lovastatin—atherosclerosis	0.000347	0.00303	CcSEcCtD
Gefitinib—Urticaria—Ezetimibe—atherosclerosis	0.000342	0.00299	CcSEcCtD
Gefitinib—Body temperature increased—Ezetimibe—atherosclerosis	0.000341	0.00298	CcSEcCtD
Gefitinib—Abdominal pain—Ezetimibe—atherosclerosis	0.000341	0.00298	CcSEcCtD
Gefitinib—Dyspnoea—Niacin—atherosclerosis	0.000336	0.00294	CcSEcCtD
Gefitinib—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000336	0.00294	CcSEcCtD
Gefitinib—Dyspnoea—Pravastatin—atherosclerosis	0.000331	0.00289	CcSEcCtD
Gefitinib—CYP2C9—cardiovascular system—atherosclerosis	0.000329	0.00876	CbGeAlD
Gefitinib—Decreased appetite—Niacin—atherosclerosis	0.000328	0.00287	CcSEcCtD
Gefitinib—Rash—Rosuvastatin—atherosclerosis	0.000327	0.00286	CcSEcCtD
Gefitinib—Dermatitis—Rosuvastatin—atherosclerosis	0.000327	0.00285	CcSEcCtD
Gefitinib—Urticaria—Simvastatin—atherosclerosis	0.000326	0.00285	CcSEcCtD
Gefitinib—ALB—liver—atherosclerosis	0.000326	0.00868	CbGeAlD
Gefitinib—Gastrointestinal disorder—Niacin—atherosclerosis	0.000326	0.00285	CcSEcCtD
Gefitinib—Abdominal pain—Simvastatin—atherosclerosis	0.000325	0.00284	CcSEcCtD
Gefitinib—Body temperature increased—Simvastatin—atherosclerosis	0.000325	0.00284	CcSEcCtD
Gefitinib—Hypersensitivity—Lovastatin—atherosclerosis	0.000324	0.00283	CcSEcCtD
Gefitinib—Decreased appetite—Pravastatin—atherosclerosis	0.000323	0.00282	CcSEcCtD
Gefitinib—Pain—Niacin—atherosclerosis	0.000323	0.00282	CcSEcCtD
Gefitinib—Fatigue—Pravastatin—atherosclerosis	0.00032	0.0028	CcSEcCtD
Gefitinib—ABCG2—adipose tissue—atherosclerosis	0.000318	0.00846	CbGeAlD
Gefitinib—Pain—Pravastatin—atherosclerosis	0.000318	0.00278	CcSEcCtD
Gefitinib—Constipation—Pravastatin—atherosclerosis	0.000318	0.00278	CcSEcCtD
Gefitinib—Hypersensitivity—Ezetimibe—atherosclerosis	0.000317	0.00277	CcSEcCtD
Gefitinib—Asthenia—Lovastatin—atherosclerosis	0.000315	0.00275	CcSEcCtD
Gefitinib—Pruritus—Lovastatin—atherosclerosis	0.000311	0.00272	CcSEcCtD
Gefitinib—Asthenia—Ezetimibe—atherosclerosis	0.000309	0.0027	CcSEcCtD
Gefitinib—Gastrointestinal pain—Niacin—atherosclerosis	0.000309	0.0027	CcSEcCtD
Gefitinib—Nausea—Rosuvastatin—atherosclerosis	0.000308	0.00269	CcSEcCtD
Gefitinib—Pruritus—Ezetimibe—atherosclerosis	0.000305	0.00266	CcSEcCtD
Gefitinib—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000304	0.00265	CcSEcCtD
Gefitinib—Hypersensitivity—Simvastatin—atherosclerosis	0.000303	0.00264	CcSEcCtD
Gefitinib—CYP1A1—adipose tissue—atherosclerosis	0.000302	0.00803	CbGeAlD
Gefitinib—Diarrhoea—Lovastatin—atherosclerosis	0.000301	0.00263	CcSEcCtD
Gefitinib—Urticaria—Niacin—atherosclerosis	0.0003	0.00262	CcSEcCtD
Gefitinib—Abdominal pain—Niacin—atherosclerosis	0.000298	0.00261	CcSEcCtD
Gefitinib—Body temperature increased—Niacin—atherosclerosis	0.000298	0.00261	CcSEcCtD
Gefitinib—Urticaria—Pravastatin—atherosclerosis	0.000295	0.00258	CcSEcCtD
Gefitinib—CYP3A5—adipose tissue—atherosclerosis	0.000295	0.00785	CbGeAlD
Gefitinib—Asthenia—Simvastatin—atherosclerosis	0.000295	0.00258	CcSEcCtD
Gefitinib—Diarrhoea—Ezetimibe—atherosclerosis	0.000295	0.00258	CcSEcCtD
Gefitinib—Abdominal pain—Pravastatin—atherosclerosis	0.000294	0.00257	CcSEcCtD
Gefitinib—Body temperature increased—Pravastatin—atherosclerosis	0.000294	0.00257	CcSEcCtD
Gefitinib—Erlotinib—ALB—atherosclerosis	0.000293	0.0836	CrCbGaD
Gefitinib—Pruritus—Simvastatin—atherosclerosis	0.000291	0.00254	CcSEcCtD
Gefitinib—Diarrhoea—Simvastatin—atherosclerosis	0.000281	0.00246	CcSEcCtD
Gefitinib—Vomiting—Lovastatin—atherosclerosis	0.000279	0.00244	CcSEcCtD
Gefitinib—Hypersensitivity—Niacin—atherosclerosis	0.000278	0.00243	CcSEcCtD
Gefitinib—Rash—Lovastatin—atherosclerosis	0.000277	0.00242	CcSEcCtD
Gefitinib—Dermatitis—Lovastatin—atherosclerosis	0.000277	0.00242	CcSEcCtD
Gefitinib—Vomiting—Ezetimibe—atherosclerosis	0.000274	0.00239	CcSEcCtD
Gefitinib—Hypersensitivity—Pravastatin—atherosclerosis	0.000274	0.00239	CcSEcCtD
Gefitinib—Rash—Ezetimibe—atherosclerosis	0.000272	0.00237	CcSEcCtD
Gefitinib—Dermatitis—Ezetimibe—atherosclerosis	0.000271	0.00237	CcSEcCtD
Gefitinib—Asthenia—Niacin—atherosclerosis	0.000271	0.00236	CcSEcCtD
Gefitinib—Pruritus—Niacin—atherosclerosis	0.000267	0.00233	CcSEcCtD
Gefitinib—Asthenia—Pravastatin—atherosclerosis	0.000267	0.00233	CcSEcCtD
Gefitinib—Pruritus—Pravastatin—atherosclerosis	0.000263	0.0023	CcSEcCtD
Gefitinib—CYP2C19—liver—atherosclerosis	0.000263	0.00699	CbGeAlD
Gefitinib—Vomiting—Simvastatin—atherosclerosis	0.000261	0.00228	CcSEcCtD
Gefitinib—Nausea—Lovastatin—atherosclerosis	0.000261	0.00228	CcSEcCtD
Gefitinib—Rash—Simvastatin—atherosclerosis	0.000259	0.00226	CcSEcCtD
Gefitinib—Dermatitis—Simvastatin—atherosclerosis	0.000259	0.00226	CcSEcCtD
Gefitinib—Diarrhoea—Niacin—atherosclerosis	0.000258	0.00226	CcSEcCtD
Gefitinib—Nausea—Ezetimibe—atherosclerosis	0.000256	0.00224	CcSEcCtD
Gefitinib—Diarrhoea—Pravastatin—atherosclerosis	0.000254	0.00222	CcSEcCtD
Gefitinib—Nausea—Simvastatin—atherosclerosis	0.000244	0.00213	CcSEcCtD
Gefitinib—Vomiting—Niacin—atherosclerosis	0.00024	0.0021	CcSEcCtD
Gefitinib—Rash—Niacin—atherosclerosis	0.000238	0.00208	CcSEcCtD
Gefitinib—Dermatitis—Niacin—atherosclerosis	0.000238	0.00208	CcSEcCtD
Gefitinib—Vomiting—Pravastatin—atherosclerosis	0.000236	0.00206	CcSEcCtD
Gefitinib—Rash—Pravastatin—atherosclerosis	0.000234	0.00205	CcSEcCtD
Gefitinib—Dermatitis—Pravastatin—atherosclerosis	0.000234	0.00204	CcSEcCtD
Gefitinib—Nausea—Niacin—atherosclerosis	0.000224	0.00196	CcSEcCtD
Gefitinib—ABCG2—liver—atherosclerosis	0.000223	0.00593	CbGeAlD
Gefitinib—Nausea—Pravastatin—atherosclerosis	0.000221	0.00193	CcSEcCtD
Gefitinib—CYP1A1—liver—atherosclerosis	0.000212	0.00563	CbGeAlD
Gefitinib—CYP3A5—liver—atherosclerosis	0.000207	0.00551	CbGeAlD
Gefitinib—CYP2C9—liver—atherosclerosis	0.000204	0.00542	CbGeAlD
Gefitinib—Vandetanib—ALB—atherosclerosis	0.000193	0.0551	CrCbGaD
Gefitinib—ABCB1—cardiovascular system—atherosclerosis	0.000178	0.00473	CbGeAlD
Gefitinib—ABCB1—adipose tissue—atherosclerosis	0.000157	0.00417	CbGeAlD
Gefitinib—CYP3A4—liver—atherosclerosis	0.000155	0.00413	CbGeAlD
Gefitinib—CYP2D6—liver—atherosclerosis	0.000153	0.00407	CbGeAlD
Gefitinib—ABCB1—liver—atherosclerosis	0.00011	0.00293	CbGeAlD
Gefitinib—EGFR—Innate Immune System—IL6—atherosclerosis	4.81e-06	3.27e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CAV1—atherosclerosis	4.81e-06	3.27e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—APOA1—atherosclerosis	4.8e-06	3.26e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL1B—atherosclerosis	4.79e-06	3.25e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—HMOX1—atherosclerosis	4.79e-06	3.25e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTGS2—atherosclerosis	4.75e-06	3.22e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PPARG—atherosclerosis	4.72e-06	3.21e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GSTM1—atherosclerosis	4.72e-06	3.2e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HMGCR—atherosclerosis	4.71e-06	3.2e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VEGFA—atherosclerosis	4.71e-06	3.2e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HMGCR—atherosclerosis	4.67e-06	3.17e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—STAT3—atherosclerosis	4.66e-06	3.16e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	4.66e-06	3.16e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALOX15—atherosclerosis	4.66e-06	3.16e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOA2—atherosclerosis	4.66e-06	3.16e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	4.66e-06	3.16e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—IL6—atherosclerosis	4.65e-06	3.16e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—AKT1—atherosclerosis	4.65e-06	3.15e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ESR1—atherosclerosis	4.64e-06	3.15e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—LPL—atherosclerosis	4.63e-06	3.15e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—INS—atherosclerosis	4.63e-06	3.14e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	4.62e-06	3.14e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MAPK3—atherosclerosis	4.62e-06	3.14e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCG5—atherosclerosis	4.6e-06	3.12e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—APOB—atherosclerosis	4.58e-06	3.11e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—F2—atherosclerosis	4.58e-06	3.11e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ABCA1—atherosclerosis	4.57e-06	3.1e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GPX1—atherosclerosis	4.52e-06	3.07e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TGFB1—atherosclerosis	4.48e-06	3.04e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NFKB1—atherosclerosis	4.47e-06	3.03e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GSTM1—atherosclerosis	4.46e-06	3.03e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ABCA1—atherosclerosis	4.46e-06	3.02e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MAPK3—atherosclerosis	4.45e-06	3.02e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—atherosclerosis	4.45e-06	3.02e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—LPA—atherosclerosis	4.44e-06	3.02e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—AKT1—atherosclerosis	4.44e-06	3.01e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CD36—atherosclerosis	4.4e-06	2.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK8—atherosclerosis	4.39e-06	2.98e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CG—atherosclerosis	4.38e-06	2.97e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—LPL—atherosclerosis	4.38e-06	2.97e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP9—atherosclerosis	4.36e-06	2.96e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—HMOX1—atherosclerosis	4.36e-06	2.96e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TGFB1—atherosclerosis	4.32e-06	2.93e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NFKB1—atherosclerosis	4.32e-06	2.93e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—BGN—atherosclerosis	4.3e-06	2.92e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—AKT1—atherosclerosis	4.29e-06	2.91e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6—atherosclerosis	4.27e-06	2.9e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GPX1—atherosclerosis	4.27e-06	2.9e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—AKT1—atherosclerosis	4.26e-06	2.89e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOA5—atherosclerosis	4.26e-06	2.89e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ALB—atherosclerosis	4.25e-06	2.88e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK8—atherosclerosis	4.24e-06	2.88e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	4.21e-06	2.86e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—MAPK3—atherosclerosis	4.21e-06	2.86e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ABCA1—atherosclerosis	4.2e-06	2.85e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—MAPK3—atherosclerosis	4.2e-06	2.85e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6—atherosclerosis	4.19e-06	2.85e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOB—atherosclerosis	4.18e-06	2.84e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—MTHFR—atherosclerosis	4.17e-06	2.83e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ABCA1—atherosclerosis	4.16e-06	2.83e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CD36—atherosclerosis	4.16e-06	2.82e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—INS—atherosclerosis	4.15e-06	2.82e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	4.1e-06	2.78e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PPARA—atherosclerosis	4.09e-06	2.78e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TGFB1—atherosclerosis	4.09e-06	2.77e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL2—atherosclerosis	4.08e-06	2.77e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTM1—atherosclerosis	4.07e-06	2.76e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—NOS3—atherosclerosis	4.06e-06	2.76e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—STAT3—atherosclerosis	4.01e-06	2.72e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IGF1—atherosclerosis	4.01e-06	2.72e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—LPL—atherosclerosis	3.99e-06	2.71e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AGT—atherosclerosis	3.96e-06	2.69e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALOX5—atherosclerosis	3.96e-06	2.69e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKT1—atherosclerosis	3.94e-06	2.68e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—MTHFR—atherosclerosis	3.94e-06	2.68e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—atherosclerosis	3.92e-06	2.66e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—HMOX1—atherosclerosis	3.92e-06	2.66e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GPX1—atherosclerosis	3.89e-06	2.64e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—APOE—atherosclerosis	3.88e-06	2.64e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—STAT3—atherosclerosis	3.88e-06	2.63e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—atherosclerosis	3.87e-06	2.63e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPARA—atherosclerosis	3.87e-06	2.62e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CAV1—atherosclerosis	3.85e-06	2.61e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—APOA1—atherosclerosis	3.84e-06	2.61e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK3—atherosclerosis	3.83e-06	2.6e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—HMOX1—atherosclerosis	3.82e-06	2.59e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SERPINE1—atherosclerosis	3.81e-06	2.59e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CD36—atherosclerosis	3.79e-06	2.57e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOB—atherosclerosis	3.75e-06	2.55e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AGT—atherosclerosis	3.74e-06	2.54e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—atherosclerosis	3.71e-06	2.52e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK3—atherosclerosis	3.71e-06	2.52e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—STAT3—atherosclerosis	3.71e-06	2.52e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—APOE—atherosclerosis	3.67e-06	2.49e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOB—atherosclerosis	3.66e-06	2.49e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTM1—atherosclerosis	3.65e-06	2.48e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOS3—atherosclerosis	3.64e-06	2.47e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CAV1—atherosclerosis	3.64e-06	2.47e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—APOA1—atherosclerosis	3.63e-06	2.46e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HMOX1—atherosclerosis	3.6e-06	2.45e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TGFB1—atherosclerosis	3.6e-06	2.44e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—MTHFR—atherosclerosis	3.59e-06	2.44e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—LPL—atherosclerosis	3.58e-06	2.43e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HMOX1—atherosclerosis	3.57e-06	2.42e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTM1—atherosclerosis	3.56e-06	2.42e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NAMPT—atherosclerosis	3.55e-06	2.41e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAPK3—atherosclerosis	3.54e-06	2.4e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—LIPC—atherosclerosis	3.53e-06	2.4e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPARA—atherosclerosis	3.52e-06	2.39e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOC3—atherosclerosis	3.51e-06	2.38e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CG—atherosclerosis	3.51e-06	2.38e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—LPL—atherosclerosis	3.5e-06	2.37e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GPX1—atherosclerosis	3.49e-06	2.37e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—LDLR—atherosclerosis	3.49e-06	2.37e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOB—atherosclerosis	3.45e-06	2.34e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFB1—atherosclerosis	3.43e-06	2.33e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOB—atherosclerosis	3.42e-06	2.32e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AGT—atherosclerosis	3.41e-06	2.32e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GPX1—atherosclerosis	3.41e-06	2.32e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CETP—atherosclerosis	3.41e-06	2.31e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CD36—atherosclerosis	3.4e-06	2.31e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PPARG—atherosclerosis	3.38e-06	2.3e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—atherosclerosis	3.38e-06	2.29e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTM1—atherosclerosis	3.36e-06	2.28e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOE—atherosclerosis	3.34e-06	2.27e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTM1—atherosclerosis	3.33e-06	2.26e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CD36—atherosclerosis	3.32e-06	2.26e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—INS—atherosclerosis	3.32e-06	2.25e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CAV1—atherosclerosis	3.31e-06	2.25e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CG—atherosclerosis	3.31e-06	2.25e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOA1—atherosclerosis	3.31e-06	2.24e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—LPL—atherosclerosis	3.29e-06	2.24e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—LPL—atherosclerosis	3.27e-06	2.22e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SCARB1—atherosclerosis	3.26e-06	2.21e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—atherosclerosis	3.26e-06	2.21e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL8—atherosclerosis	3.23e-06	2.19e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—MTHFR—atherosclerosis	3.23e-06	2.19e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GPX1—atherosclerosis	3.21e-06	2.18e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPARG—atherosclerosis	3.2e-06	2.17e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GPX1—atherosclerosis	3.19e-06	2.16e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARA—atherosclerosis	3.16e-06	2.15e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—MTHFR—atherosclerosis	3.15e-06	2.14e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—INS—atherosclerosis	3.13e-06	2.13e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CD36—atherosclerosis	3.13e-06	2.13e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—atherosclerosis	3.12e-06	2.12e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CD36—atherosclerosis	3.1e-06	2.11e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARA—atherosclerosis	3.09e-06	2.1e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HMGCR—atherosclerosis	3.08e-06	2.09e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—atherosclerosis	3.07e-06	2.08e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AGT—atherosclerosis	3.06e-06	2.08e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ALB—atherosclerosis	3.04e-06	2.06e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CG—atherosclerosis	3.02e-06	2.05e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—atherosclerosis	3e-06	2.04e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOE—atherosclerosis	3e-06	2.04e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AGT—atherosclerosis	2.99e-06	2.03e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CAV1—atherosclerosis	2.98e-06	2.02e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOA1—atherosclerosis	2.97e-06	2.01e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MTHFR—atherosclerosis	2.97e-06	2.01e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MTHFR—atherosclerosis	2.94e-06	2e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOE—atherosclerosis	2.93e-06	1.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—atherosclerosis	2.92e-06	1.98e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPARG—atherosclerosis	2.91e-06	1.98e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARA—atherosclerosis	2.91e-06	1.98e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NOS3—atherosclerosis	2.91e-06	1.98e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CAV1—atherosclerosis	2.9e-06	1.97e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOA1—atherosclerosis	2.9e-06	1.97e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NFKB1—atherosclerosis	2.89e-06	1.96e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARA—atherosclerosis	2.89e-06	1.96e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ALB—atherosclerosis	2.87e-06	1.95e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—INS—atherosclerosis	2.86e-06	1.94e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—atherosclerosis	2.84e-06	1.93e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK8—atherosclerosis	2.84e-06	1.93e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—atherosclerosis	2.83e-06	1.92e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AGT—atherosclerosis	2.82e-06	1.91e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—atherosclerosis	2.8e-06	1.9e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AGT—atherosclerosis	2.79e-06	1.9e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOE—atherosclerosis	2.76e-06	1.87e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NOS3—atherosclerosis	2.75e-06	1.87e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCA1—atherosclerosis	2.75e-06	1.86e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOE—atherosclerosis	2.74e-06	1.86e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CAV1—atherosclerosis	2.74e-06	1.86e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOA1—atherosclerosis	2.73e-06	1.85e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CAV1—atherosclerosis	2.71e-06	1.84e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—atherosclerosis	2.71e-06	1.84e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CG—atherosclerosis	2.71e-06	1.84e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOA1—atherosclerosis	2.71e-06	1.84e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—atherosclerosis	2.66e-06	1.81e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CG—atherosclerosis	2.64e-06	1.8e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—atherosclerosis	2.62e-06	1.78e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARG—atherosclerosis	2.62e-06	1.78e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—STAT3—atherosclerosis	2.59e-06	1.76e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—atherosclerosis	2.59e-06	1.76e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—atherosclerosis	2.59e-06	1.76e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—INS—atherosclerosis	2.57e-06	1.74e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARG—atherosclerosis	2.55e-06	1.73e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—atherosclerosis	2.51e-06	1.71e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NOS3—atherosclerosis	2.51e-06	1.7e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—INS—atherosclerosis	2.5e-06	1.7e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—atherosclerosis	2.5e-06	1.7e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CG—atherosclerosis	2.49e-06	1.69e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK3—atherosclerosis	2.48e-06	1.68e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CG—atherosclerosis	2.47e-06	1.68e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARG—atherosclerosis	2.41e-06	1.63e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFB1—atherosclerosis	2.41e-06	1.63e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—atherosclerosis	2.39e-06	1.62e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARG—atherosclerosis	2.38e-06	1.62e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—INS—atherosclerosis	2.36e-06	1.6e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HMOX1—atherosclerosis	2.36e-06	1.6e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ALB—atherosclerosis	2.35e-06	1.6e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—INS—atherosclerosis	2.34e-06	1.59e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ALB—atherosclerosis	2.3e-06	1.56e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—atherosclerosis	2.29e-06	1.56e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOB—atherosclerosis	2.26e-06	1.53e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NOS3—atherosclerosis	2.25e-06	1.53e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NOS3—atherosclerosis	2.2e-06	1.49e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTM1—atherosclerosis	2.19e-06	1.49e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ALB—atherosclerosis	2.16e-06	1.47e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—LPL—atherosclerosis	2.15e-06	1.46e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ALB—atherosclerosis	2.14e-06	1.46e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GPX1—atherosclerosis	2.1e-06	1.43e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NOS3—atherosclerosis	2.07e-06	1.4e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—atherosclerosis	2.06e-06	1.4e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NOS3—atherosclerosis	2.05e-06	1.39e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CD36—atherosclerosis	2.05e-06	1.39e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—atherosclerosis	2.01e-06	1.36e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTHFR—atherosclerosis	1.94e-06	1.32e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARA—atherosclerosis	1.9e-06	1.29e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—atherosclerosis	1.89e-06	1.28e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—atherosclerosis	1.88e-06	1.27e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—atherosclerosis	1.87e-06	1.27e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AGT—atherosclerosis	1.84e-06	1.25e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—atherosclerosis	1.81e-06	1.23e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOE—atherosclerosis	1.81e-06	1.23e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CAV1—atherosclerosis	1.79e-06	1.21e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOA1—atherosclerosis	1.78e-06	1.21e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—atherosclerosis	1.67e-06	1.13e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.63e-06	1.11e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARG—atherosclerosis	1.57e-06	1.07e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—INS—atherosclerosis	1.54e-06	1.05e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALB—atherosclerosis	1.41e-06	9.6e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NOS3—atherosclerosis	1.35e-06	9.18e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—atherosclerosis	1.34e-06	9.08e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—atherosclerosis	1.26e-06	8.58e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.24e-06	8.4e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—atherosclerosis	1.15e-06	7.82e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—atherosclerosis	1.03e-06	7.02e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—atherosclerosis	1.01e-06	6.85e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—atherosclerosis	9.51e-07	6.46e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—atherosclerosis	9.43e-07	6.4e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—atherosclerosis	6.22e-07	4.22e-06	CbGpPWpGaD
